The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Future therapeutic strategies for HCC
Arndt Vogel, MD, PhD, of Hannover Medical School, Hannover, Germany, discusses combination therapies, particularly immuno agents plus local therapy, for the future of hepatocellular carcinoma (HCC) treatment. Prof. Vogel suggests that immunotherapy could enhance the response of HCC patients who receive local or systemic therapy. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
